LBLucas Crespo de Barros

Lucas Crespo de Barros

*This is an algorithmically generated author record based on publicly available information.

Lucas Crespo de Barros has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mixoma Atrial Gigante em Gestante: Relato de Caso

    by Roberto Ramos Barbosa, Caio Badiani Prando, Victor Macedo Bianchini, Lucas Crespo de Barros, Larissa Novaes Paganini, Gracielly Barros, Darlan Dadalt, Sergio Luis Santos Guedes, Vinicius Eduardo Araújo Costa, Marcus Gustavo Tito, et al.

  • Giant Atrial Myxoma in a Pregnant Patient: A Case Report

    by Roberto Ramos Barbosa, Caio Badiani Prando, Victor Macedo Bianchini, Lucas Crespo de Barros, Larissa Novaes Paganini, Gracielly Barros, Darlan Dadalt, Sergio Luis Santos Guedes, Vinicius Eduardo Araújo Costa, Marcus Gustavo Tito, et al.

  • Open Access

    Gerbode defect secondary to tricuspid valve endocarditis: a case report

    by Roberto Ramos Barbosa, Layla Pasolini Lott, Layane Bonfante Batista, Anna Júlia Curcio de Paula Allemand, Vinicius Eduardo Araújo Costa, Sergio Luís Santos Guedes, Bárbara Keller Schreiber, Lucas Crespo de Barros, Rodolfo Costa Sylvestre, Luiz Fernando Machado Barbosa

    The Gerbode defect is characterized by a high ventricular septal defect associated with a defect in the septal leaflet of the tricuspid valve, allowing blood to enter the right atrium from the left ventricle. It accounts for approximately 0.08% of intracardiac shunts and may be congenital or acquired. We describe a rare case of Gerbode defect secondary to tricuspid valve endocarditis. A 58-year-old male patient presented with acute infective endocarditis due to Staphylococcus aureus, related to central venous access. Echocardiography showed a tricuspid valve with thickened leaflets and a small mobile image on the atrial side of the septal leaflet, as well as moderate to severe regurgitation. After completion of the antibiotic regimen with resolution of the infectious condition, the patient was discharged asymptomatic, and a new echocardiogram showed no vegetation on the tricuspid valve. During outpatient follow-up, he presented dyspnea on mild exertion, and consecutive echocardiograms showed moderate tricuspid insufficiency and significant pulmonary hypertension with a pulmonary artery systolic pressure of 83 mmHg (reference: 30 mmHg). He underwent right and left cardiac catheterization, which showed a Gerbode defect, and a transesophageal echocardiogram showed a shunt in the subaortic region measuring 6 to 8 mm, with a maximum gradient of 56 mmHg. He underwent elective surgery to correct the Gerbode defect and tricuspid valve repair, with a good clinical result. The Gerbode defect is rare, and the diagnosis can be challenging because it simulates other conditions. Treatment consists of closing the defect when it generates refractory symptoms or complications. The reported case was surgically corrected, with a good result and favorable evolution.

  • Open Access

    Delay Times in Acute Myocardial Infarction Care: Comparison Between Periods Before and During the COVID-19 Pandemic

    by Layla Pasolini Lott, Roberto Ramos Barbosa, Rhaaby Rodrigues Muzi, Camila Marianelli, Isadora Cardozo Bragatto, Valentin Trevizani, Glícia Chierici Baptista, Eduardo Gomes Vieira, Rodolfo Costa Sylvestre, Osmar Araújo Calil, et al.

    Background The success of acute myocardial infarction with ST-segment elevation (STEMI) treatment is time-dependent, requiring prompt access, diagnosis, and immediate medical intervention. The COVID-19 pandemic has significantly impacted the care of patients with STEMI. Objective To analyze delay times and clinical outcomes of patients with STEMI undergoing primary percutaneous coronary intervention (PPCI) before and during the COVID-19 pandemic. Methods This retrospective observational study included patients with STEMI undergoing PPCI from June 2019 to July 2022. The COVID-19 pandemic period [...] Abstract Background The success of acute myocardial infarction with ST-segment elevation (STEMI) treatment is time-dependent, requiring prompt access, diagnosis, and immediate medical intervention. The COVID-19 pandemic has significantly impacted the care of patients with STEMI. Objective To analyze delay times and clinical outcomes of patients with STEMI undergoing primary percutaneous coronary intervention (PPCI) before and during the COVID-19 pandemic. Methods This retrospective observational study included patients with STEMI undergoing PPCI from June 2019 to July 2022. The COVID-19 pandemic period

  • Open Access

    Endocardite bacteriana causada por Ochrobactrum anthropi: relato de caso / Bacterial endocarditis caused by Ochrobactrum anthropi: case report

    by Beatriz Dias da Costa, Diandra Zapata Galvêas Miranda, Luana Manhães Ferreira, Maria das Graças Silva Mattede, José Augusto Murad, Luciana Galvêas de Miranda, Lucas Crespo de Barros

    Introdução: A endocardite infecciosa é uma lesão inflamatória do endocárdio e das valvas cardíacas. Possui predileção pelo sexo masculino e idade maior que 65 anos. O uso de drogas intravenosas, procedimentos odontológicos cirúrgicos e doença cardíaca reumática são fatores que favorecem seu desenvolvimento. O quadro clínico é diversificado e não específico, o que dificulta seu diagnóstico. Associando a clínica com exame de imagem e dados microbiológicos, e baseando-se nos Critérios Duke Modificados, é possível fazer o diagnóstico definitivo. Entre os patógenos causadores de endocardite raramente relatados, está a bactéria Ochrobactrum anthropi. Essa espécie apresenta resistência a vários antibióticos utilizados na clínica, como os betalactâmicos. De forma geral, é sensível à gentamicina, polimixinas, sulfametoxazol-trimetoprim e fluoroquinolonas. Objetivo: Relatar um caso de endocardite bacteriana causada por Ochrobactrum anthropi. Relato do caso: Paciente, 30 anos, sexo masculino, sem comorbidades prévias, médico. Em novembro de 2019, iniciou quadro de cefaleia e febre. Ante a hipótese de sinusite bacteriana aguda, fez uso de amoxicilina com clavulanato, com melhora total do quadro. Os sintomas retornaram e iniciou uso de levofloxacino, com melhora parcial. Buscou o Hospital Santa Rita, onde detectou-se sopro cardíaco sistólico em foco aórtico, sendo solicitado um ecocardiograma transtorácico que evidenciou comunicação interventricular e imagem pedunculada móvel sugestiva de vegetação. Foi internado para receber antibioticoterapia de amplo espectro, com ceftriaxone e vancomicina, pelo total de seis semanas. Para correção das lesões, realizou ventriculosseptoplastia, atriosseptorrafia, plastia de valva aórtica e retirada das lesões vegetantes em 09 de novembro de 2020, no Hospital Unimed de Vitória. O fragmento do tecido cardíaco retirado em cirurgia foi enviado ao laboratório Tommasi para realização de exames, nos quais observou-se a presença de bastonetes gram-negativos, identificados como a bactéria Ochrobactrum anthropi. Iniciou tratamento com meropenem e recebeu alta em 19 de novembro de 2020. Concluiu a antibioticoterapia em domicílio até finalizar seis semanas. Conclusão: O Ochrobactrum anthropi é um agente etiológico raro, e essas informações sobre endocardite bacteriana podem favorecer a elucidação de infecções de difícil diagnóstico, ampliando a possibilidade de abordagem terapêutica mais adequada do paciente. Palavras-chave: Endocardite, Valva aórtica, Ochrobactrum anthropi ABSTRACT: Introduction: Infectious endocarditis is an inflammatory lesion of the endocardium and heart valves. It has a predilection for males and over 65 years of age. The use of intravenous drugs, surgical dental procedures and rheumatic heart disease are factors that favor its development. The clinical picture is diverse and non-specific, which makes its diagnosis difficult. Associating the clinic with imaging and microbiological data, and based on the Modified Duke Criteria, it is possible to make a definitive diagnosis. Among the rarely reported endocarditis-causing pathogens is the bacterium Ochrobactrum anthropi. This species is resistant to several antibiotics used in the clinic, such as beta-lactams. It is generally sensitive to gentamicin, polymyxins, sulfamethoxazole-trimethoprim and fluoroquinolones. Objective: To report a case of bacterial endocarditis caused by Ochrobactrum anthropi. Case report: Thirty year-old, male patient, without previous comorbidities, a physician. In November 2019 he started having a headache and fever. With the hypothesis of acute bacterial sinusitis, he used amoxicillin with clavulanate, with total improvement of symptoms. However, the symptoms returned, causing him to use levofloxacin, with partial improvement of the condition. He went to Hospital Santa Rita, where a systolic heart murmur was detected in the aortic area, and a transthoracic echocardiogram was requested, which showed interventricular communication and a mobile pedunculated image suggestive of vegetation. He was admitted to receive broad-spectrum antibiotic therapy, with ceftriaxone and vancomycin, for a total of six weeks. To correct the lesions, he performed ventriculoseptoplasty, direct suture of the atrial septum, aortic valve repair and removal of vegetating lesions on November 9, 2020, at Hospital Unimed de Vitória. The surgically removed cardiac tissue fragment was sent to the Tommasi laboratory for examinations, in which the presence of gram-negative rods, identified as the Ochrobactrum anthropi bacteria, was observed. He started treatment with meropenem and was discharged on November 19, 2020. He completed antibiotic therapy at home until the end of six weeks. Conclusion: Ochrobactrum anthropi is a rare etiologic agent and this information on bacterial endocarditis can favor the elucidation of infections that are difficult to diagnose, expanding the possibility of a more adequate therapeutic approach for the patient. Keywords: Endocarditis, Aortic valve, Ochrobactrum anthropi